Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous T-cell lymphoma. New immunomodulators.

N Apisarnthanarax1, M Duvic

  • 1Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

Dermatologic Clinics
|November 14, 2001
PubMed
Summary

Recent advances in understanding cutaneous T-cell lymphoma (CTCL) have led to effective immunomodulators. Recombinant cytokines and retinoids show promise for CTCL treatment, with further research into cytokine profiles guiding future therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second primary malignancies in subcutaneous panniculitis-like T-cell lymphoma: a national database study.

Clinical and experimental dermatology·2020
Same author

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides.

The British journal of dermatology·2018
Same author

Successful Suppression of Recurrent Zosteriform Mycosis Fungoides With Maintenance Valacyclovir.

Actas dermo-sifiliograficas·2018
Same author

Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia.

Clinical and experimental dermatology·2018

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Significant progress has been made in understanding the immunologic and pathologic mechanisms of cutaneous T-cell lymphoma (CTCL).
  • This understanding has driven the development of novel immunomodulatory therapies targeting aberrant immune responses and cellular processes in CTCL.

Purpose of the Study:

  • To review currently available immune-response modifying drugs for CTCL treatment.
  • To assess the efficacy and toxicity profiles of these agents.
  • To identify potential future therapeutic strategies based on immunologic aberrations.

Main Methods:

  • Literature review of immune-response modifying drugs for CTCL.
  • Analysis of efficacy and safety data for cytokines and retinoids.

Related Experiment Videos

  • Evaluation of the role of specific agents like bexarotene, IL-12, and IFN-alpha.

    • Main Results:

    • Recombinant cytokines and retinoids demonstrate tolerable toxicity and substantial efficacy in CTCL treatment.
    • FDA-approved drugs like bexarotene are available, and agents such as IL-12 show potential.
    • Interferon-alpha (IFN-alpha), though unapproved, appears to be a highly active single immunomodulating agent against CTCL.

    Conclusions:

    • Current immunomodulators offer effective treatment options for CTCL.
    • Further research into CTCL-specific cytokine profiles and immunologic alterations is crucial.
    • Developing targeted immunomodulators to reverse these specific alterations holds promise for improved CTCL therapies.